Your shopping cart is empty

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

Check out our free and informative ezines and sign up now

Home > Newsletters > Drug Industry Daily > Endo Petitions FDA to Maintain Opana Control as More Generic Companies Submit ANDAs

Drug Industry Daily

Oct. 1, 2012 | Vol. 11 No. 192

Endo Petitions FDA to Maintain Opana Control as More Generic Companies Submit ANDAs

Endo Pharmaceuticals is petitioning the FDA to require generics referencing its crush-resistant pain drug, Opana ER CRF, demonstrate they are similarly crush-resistant.

This article is viewable by subscribers only. To view this article, please select an option below.

Subscribe
Print This Page
Email This Article
RSS
Free Trial
Archives
Sample PDF

FDA Delivers Final Blow to Generic Drugmakers Eyeing OxyContin Copycats FDA Questions Reckitt’s Motives in Petition Denial, OKs Suboxone ANDAs FDA Questions Reckitt Benckiser’s Motives in Petition Denial, OKs Two Suboxone Generics FDA: More Work May Be Needed to Discourage Anticompetitive Petitions

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.